Asia-Pacific Rapid Diagnostic Tests (RDT) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Asia-Pacific Rapid Diagnostic Tests (RDT) Market Size

• The Asia-Pacific rapid diagnostic tests (RDT) market size was valued at USD 15.86 billion in 2024 and is expected to reach USD 34.50 billion by 2032, at a CAGR of 10.20% during the forecast period
• The market growth is largely driven by the increasing prevalence of infectious diseases, rising awareness about early disease detection, and expanding healthcare access across emerging economies in the region, leading to higher adoption of quick and reliable point-of-care diagnostics
• Furthermore, government initiatives to strengthen disease surveillance, along with advancements in RDT technologies offering improved accuracy, portability, and affordability, are positioning these tests as an essential tool for timely diagnosis. These converging factors are accelerating the adoption of RDT solutions, thereby significantly boosting the industry’s growth

Asia-Pacific Rapid Diagnostic Tests (RDT) Market Analysis

• Rapid diagnostic tests (RDTs), designed to deliver quick and reliable results for detecting infectious diseases and health conditions, are becoming indispensable in both clinical and field applications across Asia-Pacific due to their portability, ease of use, and minimal infrastructure needs
• The adoption of RDTs is primarily driven by the increasing prevalence of communicable diseases, rising public health awareness, and the pressing need for timely diagnosis to enable faster treatment and outbreak control, especially in rural and underserved populations
• China dominated the rapid diagnostic tests (RDT) market with the largest revenue share of 39.1% in 2024, supported by extensive disease surveillance programs, strong domestic manufacturing capabilities, and government-backed healthcare initiatives, with significant uptake seen in large-scale screening for infectious diseases
• India is expected to be the fastest-growing country in the rapid diagnostic tests (RDT) market during the forecast period, driven by its large population, rising healthcare expenditure, and nationwide efforts to integrate rapid testing into public health systems
• The infectious disease testing segment dominated the rapid diagnostic tests (RDT) market with a market share of 47.3% in 2024, fueled by strong demand for malaria, dengue, HIV, and COVID-19 rapid tests, alongside continuous technological improvements enhancing test accuracy and affordability

Report Scope and Asia-Pacific Rapid Diagnostic Tests (RDT) Market Segmentation  

Asia-Pacific Rapid Diagnostic Tests (RDT) Market Trends

Technological Advancements Driving Accuracy and Accessibility

• A significant and accelerating trend in the Asia-Pacific rapid diagnostic tests (RDT) market is the incorporation of advanced diagnostic technologies such as AI-driven data analysis, microfluidics, and smartphone-based result interpretation to improve speed, accuracy, and accessibility of testing. This shift is enabling more precise and timely disease detection, particularly in remote and resource-limited areas
  • For instance, in March 2024, India-based Molbio Diagnostics expanded its AI-powered Truenat platform, offering rapid, portable, and highly sensitive molecular tests for tuberculosis and COVID-19 that can deliver results within an hour. Similarly, China’s Wondfo Biotech introduced smartphone-integrated rapid test readers that allow real-time result sharing with healthcare providers
• AI integration in RDT devices facilitates automated interpretation of test strips, reducing human error and enhancing consistency in diagnostics. Some portable systems now leverage cloud-based analytics to aggregate regional health data, supporting faster public health responses during outbreaks
• The integration of RDTs with mobile applications also allows end-users to track testing history, receive medical advice, and link results to telemedicine platforms, creating a connected healthcare ecosystem
• This trend toward intelligent, portable, and digitally integrated RDT solutions is reshaping healthcare delivery in Asia-Pacific by making reliable diagnostics more accessible to rural populations and enabling rapid response to disease outbreaks. Consequently, companies such as SD Biosensor and Abbott are launching advanced RDT kits with enhanced connectivity features, targeting both professional healthcare settings and at-home users
• The demand for RDTs that combine high sensitivity with portability and digital connectivity is growing rapidly across the region, driven by government health programs, infectious disease surveillance initiatives, and a rising preference for decentralized diagnostics

Asia-Pacific Rapid Diagnostic Tests (RDT) Market Dynamics

Driver

Rising Disease Burden and Expanding Healthcare Access

• The increasing prevalence of infectious diseases such as malaria, dengue, HIV, tuberculosis, and respiratory illnesses, combined with a growing emphasis on early detection and disease control, is a major driver of the Asia-Pacific RDT market
  • For instance, in February 2024, the Chinese Center for Disease Control and Prevention (China CDC) announced an expansion of nationwide screening programs for influenza and COVID-19, relying heavily on rapid diagnostic kits for mass testing
• Expanding healthcare access through government-led initiatives and NGO-supported programs is boosting the adoption of RDTs in rural and semi-urban areas where laboratory infrastructure is limited
• The portability, ease of use, and quick turnaround times of RDTs make them especially valuable for field health workers, emergency response teams, and community clinics
• Furthermore, the shift toward self-testing kits for conditions such as pregnancy, HIV, and COVID-19 is broadening the consumer base, supported by growing retail and e-commerce availability of approved RDT products

Restraint/Challenge

Regulatory Barriers and Quality Assurance Concerns

• Variability in regulatory frameworks and product quality across Asia-Pacific countries presents a challenge to market expansion. Inconsistent standards can lead to the circulation of substandard or counterfeit RDT kits, undermining trust among healthcare providers and patients
  • For instance, in 2023, India’s drug regulatory authority recalled several batches of imported rapid COVID-19 tests over accuracy concerns, highlighting the need for stricter quality monitoring
• In addition, while technological advancements are improving test performance, the lack of uniform certification and approval processes across the region can delay market entry for innovative products
• Addressing these issues through harmonized regulatory standards, strengthened post-market surveillance, and public awareness campaigns about purchasing certified products is crucial
• Cost constraints remain another barrier in low-income areas, where affordability can limit access despite the proven public health benefits of RDTs. Developing more low-cost, high-accuracy solutions and leveraging government subsidies or donor funding will be key to overcoming this challenge

Asia-Pacific Rapid Diagnostic Tests (RDT) Market Scope

The market is segmented on the basis of product type, mode, technology, modality, age group, test type, approach, specimen, application, end user, and distribution channel.

• By Product Type

On the basis of product type, the Asia-Pacific rapid diagnostic tests (RDT) market is segmented into consumables and kits, instruments, and others. The consumables and kits segment dominated the market with the largest revenue share of 68.4% in 2024, driven by high repeat purchases for infectious disease testing, glucose monitoring, and pregnancy testing. Single-use kits and reagents are widely preferred due to their convenience and safety, supporting adoption in hospitals, clinics, and home care settings. Large-scale public health programs for diseases such as malaria, dengue, tuberculosis, and COVID-19 create consistent demand for consumables. Moreover, these kits are cost-effective, easy to transport, and do not require specialized infrastructure. The segment also benefits from ongoing product innovations that improve sensitivity, specificity, and usability.

The instruments segment is anticipated to witness the fastest growth rate of 14.9% from 2025 to 2032, fueled by the increasing adoption of compact, portable analyzers and smartphone-compatible readers. These instruments provide faster, more accurate results, particularly for multiplex testing and molecular diagnostics. Healthcare facilities, diagnostic laboratories, and field health workers are increasingly adopting instruments for point-of-care use. Instruments also support integration with digital health platforms for real-time data tracking and remote monitoring. Growing investments in portable, easy-to-use devices for rural healthcare deployment are driving further market growth.

• By Mode

On the basis of mode, the Asia-Pacific rapid diagnostic tests (RDT) market is segmented into professional rapid diagnostic test products and over-the-counter (OTC) rapid diagnostic test products. The professional RDT product segment held the largest revenue share in 2024 due to its extensive use in hospitals, diagnostic laboratories, and government-led screening campaigns. These products are crucial for outbreak control and mass testing initiatives, providing reliable, clinically validated results. Professional RDTs are also preferred for confirmatory diagnostics and complex testing procedures. Training and quality control measures associated with professional RDTs enhance their reliability in healthcare settings. Large-scale programs for infectious diseases, including HIV, hepatitis, and malaria, continue to sustain the segment’s dominance.

The OTC RDT product segment is expected to grow at the fastest CAGR of 16.2% from 2025 to 2032, fueled by rising consumer awareness and preference for self-testing. OTC kits are increasingly used for conditions such as pregnancy, HIV, COVID-19, and influenza, providing convenience and rapid results at home. Easy availability through pharmacies and online platforms further drives adoption. Regulatory approvals for self-use RDTs enhance consumer confidence in these products. Home testing empowers individuals to monitor their health proactively. The segment benefits from continuous innovation in user-friendly designs and digital result interpretation.

• By Technology

On the basis of technology, the Asia-Pacific rapid diagnostic tests (RDT) market is segmented into PCR-based, flow-through assays, lateral flow immunochromatographic assays, agglutination assay, microfluidics, substrate technology, and others. The lateral flow immunochromatographic assays segment dominated the market with a share of 41.5% in 2024, owing to their low cost, ease of use, and suitability for rapid, point-of-care diagnostics. These assays are widely applied for infectious disease detection in professional and home settings. They are portable, require minimal training, and provide results within minutes. Their ability to be used in remote and resource-limited areas reinforces their market leadership. Additionally, manufacturers are improving sensitivity and specificity to enhance diagnostic reliability.

The microfluidics segment is projected to register the fastest CAGR of 17.8% from 2025 to 2032, driven by the capability to deliver high-accuracy results using minimal sample volumes. Microfluidic platforms enable multiplex testing, integration with portable devices, and automation of sample processing. These platforms are increasingly applied in infectious disease detection, oncology, and cardiometabolic testing. Rising investments in research and development are fueling innovation in lab-on-chip technologies. Microfluidics also enhances rapid testing in decentralized settings, making it ideal for field diagnostics. The adoption of smartphone-integrated microfluidic readers is further expanding the segment.

• By Modality

On the basis of modality, the Asia-Pacific rapid diagnostic tests (RDT) market is segmented into laboratory-based tests and non-laboratory-based tests. The non-laboratory-based test segment held the largest revenue share in 2024, driven by the expansion of point-of-care diagnostics and home healthcare solutions. Adoption is high in rural and resource-limited areas where centralized labs are scarce. Non-laboratory RDTs provide rapid results, ease of sample collection, and portability for community testing programs. These tests are widely used for infectious diseases, pregnancy, and chronic disease monitoring. They reduce dependency on clinical infrastructure and allow immediate intervention. Government and NGO programs promoting decentralized testing are further supporting growth.

The laboratory-based test segment is anticipated to see steady growth during the forecast period, particularly for confirmatory diagnostics and complex molecular testing. Hospitals, diagnostic centers, and research institutes rely on lab-based RDTs for accuracy, data integration, and quality assurance. Laboratory tests are essential for viral sequencing, serological analysis, and multi-pathogen detection. Technological advancements, such as high-throughput analyzers and automation, are enhancing lab efficiency. Adoption in reference laboratories and academic research is increasing.

• By Age Group

On the basis of age group, the Asia-Pacific rapid diagnostic tests (RDT) market is segmented into adult and pediatric. The adult segment accounted for the largest share in 2024, primarily due to higher testing volumes for chronic diseases, infectious diseases, and preventive health screening. Adults undergo frequent testing for diabetes, cardiovascular conditions, and sexually transmitted infections. Workplace health programs, insurance-mandated checkups, and screening campaigns contribute to high demand. Accessibility of both professional and OTC RDTs for adults further supports segment growth. Increasing awareness about early disease detection drives adoption. Integration with digital health platforms encourages regular self-monitoring.

The pediatric segment is expected to grow faster during the forecast period, driven by increased use in neonatal and child health programs. RDTs for malaria, respiratory infections, and congenital diseases are increasingly adopted in clinics, hospitals, and schools. Easy-to-use kits for pediatric populations enable rapid, non-invasive sample collection. Government vaccination and screening programs enhance segment penetration. Growth is also supported by parent awareness campaigns. Early disease detection in children improves clinical outcomes, further fueling demand.

• By Test Type

On the basis of test type, the Asia-Pacific rapid diagnostic tests (RDT) market is segmented into determining confirmation, serological testing, and viral sequencing. The serological testing segment held the largest share in 2024, supported by its extensive use in large-scale screening for infectious diseases. These tests are widely applied in hospitals, laboratories, and community health programs. Serological assays detect antibodies, offering insight into disease exposure and immunity levels. They are essential for epidemiological studies and vaccine efficacy monitoring. Cost-effectiveness, ease of use, and rapid results contribute to dominance. Continuous improvements in sensitivity and specificity enhance reliability.

The viral sequencing segment is projected to grow at the highest CAGR during the forecast period, owing to its role in tracking pathogen mutations and guiding public health interventions. Sequencing is increasingly critical for outbreak response, variant detection, and vaccine strategy planning. Adoption in reference laboratories and academic research centers is increasing. Integration with next-generation sequencing platforms is enhancing accuracy. Funding from government and global health agencies is accelerating deployment. Viral sequencing supports precision diagnostics and personalized healthcare approaches.

• By Approach

On the basis of approach, the Asia-Pacific rapid diagnostic tests (RDT) market is segmented into in-vitro diagnostic and molecular diagnostic. The in-vitro diagnostic segment dominated in 2024 due to its broad clinical applicability and ease of integration into existing healthcare systems. In-vitro RDTs are widely used for infectious diseases, cardiometabolic conditions, and pregnancy testing. They offer quick turnaround times, simple protocols, and cost-effective solutions. Hospitals, clinics, and public health programs extensively rely on these diagnostics. Widespread availability and regulatory approval support adoption. Integration with digital platforms enhances data collection and disease surveillance.

The molecular diagnostic segment is expected to see the fastest growth during the forecast period, driven by rising demand for high-accuracy testing during outbreaks. Molecular RDTs, including PCR and isothermal amplification platforms, enable detection of low viral loads and early infection. Portable, rapid molecular platforms are increasingly used in field and home settings. Technological innovations in automation and AI-assisted analysis improve efficiency. Governments are investing in molecular diagnostics for pandemic preparedness. Rising awareness of precision diagnostics further fuels growth.

• By Specimen

On the basis of specimen, the Asia-Pacific rapid diagnostic tests (RDT) market is segmented into swab, blood, urine, saliva, sputum, and others. The swab specimen segment dominated in 2024 due to its widespread use in respiratory disease testing, including COVID-19, influenza, and RSV. Swab-based RDTs are widely accepted for their accuracy, speed, and ease of collection. Healthcare facilities rely on them for outbreak control and routine screening. Portable swab collection kits are increasingly used for home and field testing. Adoption is also supported by regulatory approvals and standardized protocols. Public awareness campaigns during pandemics have increased familiarity with swab tests.

The saliva specimen segment is expected to grow fastest during the forecast period, supported by its non-invasive nature and ease of self-collection. Saliva RDTs are gaining popularity for infectious disease, genetic testing, and viral load monitoring. They eliminate the need for trained personnel and reduce risk of exposure. Integration with home testing kits and smartphone-based readers is boosting adoption. Saliva tests are also being validated for high accuracy in detecting emerging pathogens. Increasing research and regulatory support further enhance growth.

• By Application

On the basis of application, the Asia-Pacific rapid diagnostic tests (RDT) market is segmented into infectious disease testing, glucose monitoring, cardiology testing, oncology testing, cardiometabolic testing, drugs-of-abuse testing, pregnancy and fertility testing, toxicology testing, and others. The infectious disease testing segment led the market with a 47.3% share in 2024, driven by high demand for rapid diagnostics for malaria, dengue, tuberculosis, HIV, and COVID-19. Public health programs, hospital screening, and outbreak response initiatives maintain robust demand. Affordable, rapid, and portable test kits enable widespread adoption. Technological innovations improve sensitivity, specificity, and usability. Governments are prioritizing RDT deployment in rural and underserved areas.

The oncology testing segment is expected to expand rapidly during the forecast period as RDTs gain traction for early cancer detection, monitoring treatment response, and detecting recurrence. Multiplex RDTs are increasingly being developed for tumor marker profiling, enabling simultaneous detection of multiple cancer biomarkers. Integration with point-of-care devices and digital health platforms is enhancing accessibility and real-time monitoring. Growing awareness campaigns and preventive health initiatives are encouraging routine screening and early intervention. Academic and research institutes are investing in RDT-based oncology solutions to improve diagnostic accuracy.

• By End User

On the basis of end user, the Asia-Pacific rapid diagnostic tests (RDT) market is segmented into hospital and clinic, diagnostic laboratory, home care setting, research and academic institutes, and others. The hospital and clinic segment held the largest share in 2024, serving as primary hubs for diagnosis, treatment initiation, and mass screening campaigns. Hospitals rely on both professional and OTC RDTs for patient care and outbreak management. Increasing hospital expansion, modernization, and adoption of digital health systems support demand. Training and quality control measures enhance reliability. Government and NGO programs often supply hospitals with bulk RDTs. The availability of advanced instruments supports comprehensive testing.

The home care setting segment is forecast to grow fastest during the forecast period, reflecting rising acceptance of self-testing and home healthcare solutions. Consumers increasingly prefer convenient, rapid, and accurate tests for pregnancy, infectious diseases, and chronic conditions. Online marketplaces and retail pharmacies expand accessibility. Smartphone-compatible RDTs enable remote result monitoring. Home care RDTs reduce hospital visits and facilitate early disease detection. Awareness campaigns and regulatory approvals for OTC use further boost adoption.

• By Distribution Channel

On the basis of distribution channel, the Asia-Pacific rapid diagnostic tests (RDT) market is segmented into direct tender, retail sales, and others. The direct tender segment accounted for the largest market share in 2024, driven by bulk procurement for public health programs, government institutions, and hospitals. Large-scale purchasing ensures cost-effectiveness, standardized quality, and consistent supply. Governments and NGOs rely on direct tender agreements for mass screening campaigns. Institutional contracts also provide recurring revenue streams for RDT manufacturers. Supply chain efficiency and centralized procurement support this segment.

The retail sales segment is expected to grow fastest during the forecast period, supported by the expansion of pharmacy chains, e-commerce platforms, and availability of OTC rapid test kits. Increasing consumer preference for self-testing drives retail demand. Rapid access, convenience, and user-friendly designs promote adoption. Online marketplaces enhance reach to rural and urban populations. Marketing campaigns, product awareness, and regulatory approvals further encourage growth. Technological advancements in home testing kits also support retail expansion.

Asia-Pacific Rapid Diagnostic Tests (RDT) Market Regional Analysis

• China dominated the Asia-Pacific rapid diagnostic tests (RDT) market with the largest revenue share of 39.1% in 2024, supported by extensive disease surveillance programs, strong domestic manufacturing capabilities, and government-backed healthcare initiatives, with significant uptake seen in large-scale screening for infectious diseases
• The country’s leadership in RDT adoption is supported by large-scale testing campaigns for infectious diseases such as COVID-19, influenza, and tuberculosis, alongside increasing deployment of portable diagnostic devices in rural healthcare settings
• Rising healthcare investments, a growing emphasis on early disease detection, and advancements in AI-integrated and smartphone-compatible RDT technologies are further accelerating market growth, establishing China as the primary hub for both production and consumption of rapid diagnostic solutions in the Asia-Pacific region

The China Rapid Diagnostic Tests (RDT) Market Insight

The China rapid diagnostic tests (RDT) market captured the largest revenue share of 39.1% in 2024 within Asia-Pacific, driven by the nation’s extensive public health screening programs, rapid technological advancements, and strong domestic manufacturing capabilities. Large-scale disease surveillance initiatives for COVID-19, influenza, tuberculosis, and hepatitis are fueling consistent demand. The integration of AI-powered analysis and smartphone-based result interpretation into RDT devices is further enhancing diagnostic accuracy and speed. Government investments in healthcare infrastructure and the push toward rural healthcare accessibility are solidifying China’s position as the primary hub for both production and consumption of RDT solutions in the region.

India Rapid Diagnostic Tests (RDT) Market Insight

The India rapid diagnostic tests (RDT) market is projected to expand at the fastest CAGR during the forecast period, supported by nationwide disease control initiatives, rising healthcare expenditure, and increasing adoption of decentralized diagnostic solutions. The country’s high burden of infectious diseases such as malaria, dengue, and tuberculosis is driving large-scale procurement of RDT kits for both professional and community-level use. Strong growth is also fueled by the rapid expansion of home-based self-testing kits, accessible through retail and e-commerce channels. In addition, the government’s focus on strengthening diagnostic capacity under the Ayushman Bharat program is significantly boosting market penetration.

Japan Rapid Diagnostic Tests (RDT) Market Insight

The Japan rapid diagnostic tests (RDT) market is witnessing steady growth, driven by the country’s advanced healthcare infrastructure, aging population, and focus on early disease detection. High adoption of RDTs is seen for infectious diseases, cardiometabolic conditions, and oncology applications, supported by the integration of digital result tracking and telehealth platforms. Japan’s strong regulatory framework ensures high-quality diagnostic products, and domestic manufacturers are increasingly innovating with portable, user-friendly designs to meet the needs of both clinical professionals and home users. The growing use of saliva-based and non-invasive RDTs is also contributing to market expansion.

South Korea Rapid Diagnostic Tests (RDT) Market Insight

The South Korea rapid diagnostic tests (RDT) market is expanding rapidly, propelled by strong government support for infectious disease control, a technologically advanced healthcare sector, and significant domestic manufacturing capabilities. The country’s swift adoption of RDTs for COVID-19 testing showcased its ability to deploy large-scale diagnostics quickly and effectively. South Korea is also investing heavily in molecular and AI-assisted RDT technologies for diseases such as influenza, hepatitis, and sexually transmitted infections. Rising health awareness, combined with the integration of RDT devices into telemedicine services, is further driving market growth, particularly in urban centers.

Australia Rapid Diagnostic Tests (RDT) Market Insight

The Australia rapid diagnostic tests (RDT) market is expected to grow steadily over the forecast period, driven by rising awareness of preventive healthcare and the demand for rapid testing in both clinical and at-home settings. Government-led health campaigns targeting sexually transmitted infections, respiratory illnesses, and chronic diseases are boosting adoption. The increasing acceptance of self-administered testing kits, supported by robust e-commerce distribution networks, is expanding market reach. Furthermore, Australia’s emphasis on quality standards and strong ties with global diagnostic manufacturers are ensuring the availability of technologically advanced, accurate RDT solutions.

Asia-Pacific Rapid Diagnostic Tests (RDT) Market Share

The Asia-Pacific rapid diagnostic tests (RDT) industry is primarily led by well-established companies, including:

• Abbott (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Siemens Healthineers AG (Germany)
• BIOMÉRIEUX (France)
• QuidelOrtho Corporation (U.S.)
• SD Biosensor, Inc. (South Korea)
• Access Bio, Inc. (U.S.)
• Mylab Discovery Solutions Pvt. Ltd. (India)
• Fujirebio Inc. (Japan)
• BD (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Chembio Diagnostics, Inc. (U.S.)
• Oscar Medicare Pvt. Ltd. (India)
• CTK Biotech, Inc. (U.S.)
• Ellume Limited (Australia)
• Humasis Co., Ltd. (South Korea)
• Wondfo Biotech Co., Ltd. (China)
• Lumos Diagnostics Holdings Ltd. (Australia)
• InBios International, Inc. (U.S.)
• Medsource Ozone Biomedicals Pvt. Ltd. (India)

What are the Recent Developments in Asia-Pacific Rapid Diagnostic Tests (RDT) Market?

• In August 2025, Anbio (a biotech firm) expanded its point-of-care arsenal by launching a rapid chikungunya test along with an ultra-fast PCR platform to support outbreak response in the Asia-Pacific region, addressing the need for swift diagnosis during viral surges and enabling timely treatment interventions
• In July 2025, the World Health Organization (WHO) prequalified the first bundled set of three in vitro rapid diagnostic tests (RDTs) capable of simultaneously detecting HIV, hepatitis B virus (HBV), and syphilis three major infections that pose serious risks to maternal and child health marking a significant milestone in integrated diagnostics and improving access to critical testing tools in resource-limited settings
• In June 2025, a new lateral-flow test prototype was developed to enable early detection of a deadly fungal disease that surged during the COVID-19 era, offering a cost-effective and quick detection method that could be deployed widely across Asia-Pacific healthcare systems, especially in regions facing high fungal infection burdens
• In March 2025, the World Health Organization issued an Information Notice (2025/1) warning that various malaria RDTs exhibited faint positive test lines in confirmed malaria patients, raising concerns over test reliability, false-negative risks, and quality control, prompting healthcare authorities in Asia-Pacific to review procurement and usage protocols
• In February 2025, Johns Hopkins Medicine featured efforts by its Center for Innovative Diagnostics, showcasing the development of new point-of-care RDTs for infectious diseases. These advancements aim to expand diagnostic reach, cut down turnaround times, and improve rapid testing capacity globally, with a focus on applications in Asia-Pacific regions facing high infectious disease prevalence

SKU-66845